Plus Therapeutics to Present Key Findings at SABCS 2025
Plus Therapeutics, Inc. (NASDAQ: PSTV), a leading clinical-stage pharmaceutical company, is set to present groundbreaking results from its ReSPECT Phase 1 dose escalation study. This important research focuses on leptomeningeal metastases, a severe complication associated with advanced cancers. The presentation will take place during the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025.
Details on the Presentation
The spotlight of their presentation will be a poster titled "Rhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results." This presentation aims to shed light on the innovative approaches to treat this rare condition that is often associated with poor patient prognosis.
Presenter Profile
Andrew Brenner, M.D., Ph.D., who holds the position of Professor and Kolitz/Zachry Endowed Chair in Neuro-Oncology Research at the University of Texas Health Science Center, will lead the presentation. His expertise in the field of neuro-oncology makes him an ideal representative for this significant clinical milestone.
Session and Timing
The poster presentation is scheduled for December 12, 2025, at 7:39 AM CST, followed by a dedicated session at 7:00 AM CST. The venue for this notable event will be the Hemisfair 3, located in the Henry B. Gonzalez Convention Center.
Understanding Leptomeningeal Metastases
Leptomeningeal metastases represent a critical challenge in oncology, affecting roughly 5% of patients suffering from metastatic cancers. Often stemming from breast cancer, lung cancer, or melanoma, the typical median survival for these patients ranges from just 2 to 6 months. As treatment options are severely limited, this underscores the pressing need for novel therapies that offer hope for better patient outcomes.
Introducing REYOBIQ
Central to Plus Therapeutics' innovative approach is REYOBIQ (rhenium Re186 obisbemeda). This injectable radiotherapy is tailored to deliver high doses of targeted radiation directly to CNS tumors. What sets REYOBIQ apart is its capability to minimize off-target risks while maximizing therapeutic effectiveness. This radiotherapy utilizes rhenium-186, a radioisotope ideally suited for treating CNS conditions due to its optimal characteristics, including a short half-life and effective dose delivery.
Clinical Trials and Funding
The ReSPECT-GBM trial, which assesses REYOBIQ's efficacy on recurrent glioblastoma, is supported by the National Cancer Institute (NCI). Furthermore, the ReSPECT-LM study is backed by a substantial grant from the Cancer Prevention & Research Institute of Texas (CPRIT). Another trial dedicated to pediatric brain cancer, known as ReSPECT-PBC, is receiving funding from the U.S. Department of Defense.
The Role of CNSide Diagnostic, LLC
In support of their efforts, Plus Therapeutics' subsidiary, CNSide Diagnostics, focuses on developing proprietary diagnostic tests. Their CNSide CSF Assay Platform analyzes cerebrospinal fluid to identify tumor cells that have metastasized to the CNS. This process plays a vital role in improving patient management strategies for those suffering from leptomeningeal metastases.
About Plus Therapeutics
Plus Therapeutics is headquartered in Houston, Texas, and emphasizes advancing targeted radiotherapeutics for challenging CNS cancers. By integrating image-guided radiation with precise drug delivery methods, they aspire to contribute significantly to enhancing patient lives. Their ongoing development of products aims to revolutionize the treatment landscape for difficult-to-treat cancers.
Frequently Asked Questions
What is the ReSPECT study about?
The ReSPECT study is focused on evaluating a new treatment approach using REYOBIQ for patients suffering from leptomeningeal metastases.
Who will present at the SABCS?
Andrew Brenner, M.D., Ph.D., a prominent figure in neuro-oncology, will be presenting the study results.
When is the presentation scheduled?
The presentation is set for December 12, 2025, at 7:39 AM CST during the San Antonio Breast Cancer Symposium.
What is REYOBIQ?
REYOBIQ is an injectable radiotherapy aimed at delivering targeted radiation specifically to CNS tumors, with reduced risks compared to traditional therapies.
What challenges do leptomeningeal metastases present?
Leptomeningeal metastases are a severe complication with limited treatment options and a generally poor prognosis, making innovative therapies necessary.
